PIB TrackerFrom 123rd to 8th in reporting, with the patient still the missing link
The 7th National Formulary of India carries 653 drugs, a new Biovigilance Programme extends safety monitoring to transplants, and 1,150 reporting centres carry the whole system.
What happened
- Anupriya Patel launched the 7th National Formulary of India at the 6th National Pharmacovigilance Week (17-23 September 2026).
- The Biovigilance Programme of India has been approved by Government, with IPC in the lead role.
- Also launched: a Guidance Document for hospitals on device-related adverse events, and the ADR-PvPI 2.0 app for iOS.
- NFI monographs were revised to align with the National List of Essential Medicines and National Health Programmes.
- The Minister named patient reporting as the "missing link" and called for AI and data analytics in safety systems.
For Prelims
- IPC: the Indian Pharmacopoeia Commission, an autonomous institution under MoHFW, which publishes the Indian Pharmacopoeia and hosts the National Coordination Centre for PvPI.
- The three vigilance programmes: PvPI for medicines, MvPI for medical devices, and the newly approved Biovigilance Programme for transplant-related biologicals.
- NFI 2026 composition: 34 chapters, 20 appendices, 653 drugs, of which 42 are fixed-dose combinations and 30 immunologicals.
- Formulary vs Pharmacopoeia: the Formulary guides prescribing and use; the Pharmacopoeia sets quality standards for the drug itself.
- The global ranking: 123rd during 2009-2014 to 8th in contributions to the WHO patient safety database.
- ADR: an Adverse Drug Reaction. Around 1,150 reporting centres feed the national system, backed by the ADRMS and the ADR-PvPI 2.0 app.
- International standing: about 25 countries accept the Indian Pharmacopoeia; IPC joined the Pharmacopoeial Discussion Group in 2023.
- NFI history: published periodically by IPC since 2009; the 7th edition arrives in 2026, roughly one edition every two and a half years.
For UPSC: Patient safety is where health policy, drug regulation and data systems meet, and this release covers all three in one document. Use it on drug regulation and the rational use of medicines, on India as the "pharmacy of the world" where the pharmacovigilance record is the credibility argument, and on organ transplantation governance, which the Biovigilance Programme now formally covers.
What it is NOT: The release gives no count of adverse events actually reported in any year, so "8th globally in contributions" has no volume attached and cannot be compared with any other country. It gives no signal-detection outcomes - no drug withdrawn, label changed or alert issued as a result of PvPI data - which is what a pharmacovigilance system exists to produce. The 1,150 reporting centres come with no state-wise distribution and no denominator of hospitals or medical colleges. The Biovigilance Programme is announced as approved, with no budget, no timeline, no start date and no institutional structure below IPC. And patient reporting is called the missing link without any figure for how small the patient share currently is.
For Mains
Syllabus: GS2.13 · GS3.11 · Linkage L2
Anchor
India has climbed from 123rd during 2009-2014 to 8th in the world in contributions to the WHO patient safety database. The Minister announcing that climb also named what is still absent from it: patients themselves, whose reporting she called the missing link.
Substantiation (data)
The architecture is now three-part and complete in scope. PvPI covers medicines, MvPI covers devices, and the newly approved Biovigilance Programme covers medicines and biological products in organ and tissue transplantation, for donors and recipients alike. The 7th National Formulary carries 653 drugs across 34 chapters, realigned to the NLEM.
Position
The strategic point is about evidence sovereignty rather than safety alone. A country that manufactures a large share of the world's generics but imports its safety signals from other regulators is dependent in a way that trade figures do not show. Building domestic reporting capacity is what converts manufacturing scale into regulatory standing, and about 25 countries now recognise the Indian Pharmacopoeia.
Counterpoint
Rank measures participation, not performance. Contributing case reports to a global database says nothing about whether those reports generated signals, or whether any signal changed a label, a prescription or a product. None of that appears in the release.
Problematisation
The coverage question is the harder one. Around 1,150 reporting centres sit in hospitals and medical colleges, which is where the prescriptions that get written down are. Most Indian medicine use happens outside that network, and the stated plan to extend to primary healthcare carries no target, timeline or budget.
Conclusion
The institutional build is real and the sequencing is sensible - standards first, then devices, now transplant biologicals. The system's reach is still defined by where the reporting centres are, and until that changes, the eighth-place ranking measures the part of Indian healthcare that already keeps records.
Deploys into: Drug regulation and rational use of medicines · India as pharmacy of the world · Organ transplantation governance · Health data systems and reporting
Ministry of Health and Family Welfare · 2026-09-21 · PRID 2312930 · PIB source ↗